Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

NCT00454818 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Failure, Congestive
Dilated Cardiomyopathy

Interventions

GENETIC: MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)
PROCEDURE: Placebo Infusion
GENETIC: MYDICAR Phase 2 (Placebo-controlled, Randomized Study)

Sponsor

Celladon Corporation